Financial reports
10-K
2023 FY
Annual report
18 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
25 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Mar 24
8-K
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18 Mar 24
8-K
Other Events
15 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
8 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
23 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
12 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Nov 23
8-K
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13 Nov 23
8-K
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
2 Nov 23
Registration and prospectus
424B3
Prospectus supplement
2 Feb 24
S-3
Shelf registration
24 Jan 24
424B4
Prospectus supplement with pricing info
2 Nov 23
S-1/A
IPO registration (amended)
23 Oct 23
FWP
Free writing prospectus
5 Oct 23
FWP
Free writing prospectus
3 Oct 23
S-1/A
IPO registration (amended)
29 Sep 23
S-1
IPO registration
18 Sep 23
424B3
Prospectus supplement
28 Jun 23
S-3
Shelf registration
16 Jun 23
Proxies
DEF 14C
Information statement
18 Mar 24
PRE 14C
Preliminary information
8 Mar 24
DEF 14C
Information statement
29 Jan 24
PRE 14C
Preliminary information
17 Jan 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
17 Jan 23
DEFA14A
Additional proxy soliciting materials
4 Jan 23
DEFA14A
Additional proxy soliciting materials
18 Nov 22
DEF 14A
Definitive proxy
18 Nov 22
Other
EFFECT
Notice of effectiveness
2 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
29 Jan 24
EFFECT
Notice of effectiveness
1 Nov 23
CORRESP
Correspondence with SEC
30 Oct 23
CORRESP
Correspondence with SEC
30 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
CORRESP
Correspondence with SEC
27 Oct 23
CORRESP
Correspondence with SEC
24 Oct 23
CORRESP
Correspondence with SEC
24 Oct 23
Ownership
SC 13D/A
Fortress Biotech, Inc.
17 Apr 24
4
Change in insider ownership
17 Apr 24
4
Change in insider ownership
3 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
Davidow Robert L
13 Dec 23
4
Robert L Davidow
13 Dec 23
SC 13G
Davidow Robert L
28 Nov 23
3
Robert L Davidow
28 Nov 23
SC 13D/A
Fortress Biotech, Inc.
18 Sep 23
4
LINDSAY A MD ROSENWALD
12 Sep 23